535 related articles for article (PubMed ID: 31655295)
1. C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema.
Kaplan AP; Pawaskar D; Chiao J
J Allergy Clin Immunol Pract; 2020 Mar; 8(3):892-900. PubMed ID: 31655295
[TBL] [Abstract][Full Text] [Related]
2. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
5. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
Jacobs J; Neeno T
Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
[TBL] [Abstract][Full Text] [Related]
6. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
8. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.
Henry Li H; Riedl M; Kashkin J
Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
10. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.
Valerieva A; Caccia S; Cicardi M
Expert Rev Clin Immunol; 2018 Sep; 14(9):707-718. PubMed ID: 30021471
[TBL] [Abstract][Full Text] [Related]
14. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
[TBL] [Abstract][Full Text] [Related]
16. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Hereditary Angioedema.
Caballero T
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
[TBL] [Abstract][Full Text] [Related]
18. A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable.
Longhurst HJ; Valerieva A
J Asthma Allergy; 2023; 16():269-277. PubMed ID: 36922963
[TBL] [Abstract][Full Text] [Related]
19. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.
Suffritti C; Zanichelli A; Maggioni L; Bonanni E; Cugno M; Cicardi M
Clin Exp Allergy; 2014 Dec; 44(12):1503-14. PubMed ID: 24552232
[TBL] [Abstract][Full Text] [Related]
20. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]